Thirty-eight subjects with single-level, mild to moderate lumbar degenerative disc disease will be evaluated for safety, primary efficacy and secondary outcome measures over six months. Participants will continue to be followed for a six-month extension period.
“In preclinical observations of IDCT’s human discogenic cells in a canine disc degeneration model, I observed their ability to stop disc height degeneration while improving the structure of the intervertebral disc,” Dr. Daisuke Sakai, the study’s principal investigator, said in an April 26 news release. “If similar results are achieved in humans, the result could be reduced pain and disability associated with disc degeneration.”
DiscGenics’ U.S. clinical trial of IDCT treated all 60 subjects and reported no safety issues, according to the company. All subjects completed one-year follow-ups in the U.S. study, which has a one-year extension period.
More articles on biologics:
Why more spine surgeons are looking to invest in ASCs
‘A game-changer’: One spine surgeon’s experience relocating from Brazil to the U.S.
$33M flagship facility opened by 25-physician orthopedic group
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
